Zimmer Biomet (ZBH) Reports Q4 2024 Earnings with Revenue Growth and Margin Improvements
Zimmer Biomet (ZBH) reported Q4 2024 earnings with a 4.9% year-over-year revenue growth in constant currency, continuing a twelve-quarter streak of mid-single-digit gains. The company saw growth in its Global S.E.T. segment and both knees and hips segments, while adjusted operating margin increased to 30.8%. However, GAAP diluted EPS declined due to higher non-operating expenses and taxes.
Tickers: $ZBH
Topics: earnings EPS free cash flow operating margin revenue growth stock repurchase